[Ip-health] Drug with rage-inducing >5, 000% price-hike now has $1/pill competitor

ed.silverman at comcast.net ed.silverman at comcast.net
Thu Oct 22 14:34:05 PDT 2015

lots more information in this story about the competition to Martin Shkreli 


----- Original Message -----

From: "Claire Cassedy" <claire.cassedy at keionline.org> 
To: ip-health at lists.keionline.org 
Sent: Thursday, October 22, 2015 5:29:29 PM 
Subject: [Ip-health] Drug with rage-inducing >5, 000% price-hike now has $1/pill competitor 


Drug with rage-inducing >5,000% price-hike now has $1/pill competitor 

Different company developed alternative in response to $750-per-pill price 

by Beth Mole - Oct 22, 2015 2:17pm EDT 

Turing Pharmaceuticals, the company that last month raised the price of the 
decades-old drug Daraprim from $13.50 a pill to $750, now has a competitor. 

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company based in 
San Diego, announced today that it has made an alternative to Daraprim that 
costs about a buck a pill—or $99 for a 100-pill supply. 

“While we respect Turing's right to charge patients and insurance companies 
whatever it believes is appropriate, there may be more cost-effective 
compounded options for medications, such as Daraprim,” Mark L. Baum, CEO of 
Imprimis, said in a news release. 

The alternative is not exactly the same as Daraprim, but it’s close. 
Daraprim’s active ingredient is pyrimethamine, which has been available 
since 1953 for the treatment of parasitic diseases (namely malaria and 
toxoplasmosis). Imprimis’ alternative also contains pyrimethamine as well 
as leucovorin, which the company said helps to reverse pyrimethamine’s 
negative effects on bone marrow. 

Until now, Turing was the sole producer of a pyrimethamine-based drug, 
which is often prescribed to patients with compromised immune systems such 
as those suffering from AIDS and cancer. 

The price increase of Daraprim, announced last month, sparked widespread 
outrage against the company and its founder and chief executive, Martin 
Shkreli. The move by Imprimis is in direct response to those events, and 
the company said it plans to produce more cheap alternative drugs. In the 
news release, the company announced the start of a new program called 
Imprimis Cares, which will ensure affordable versions of the 7,800 generic 
FDA-approved drugs. 
Ip-health mailing list 
Ip-health at lists.keionline.org 

More information about the Ip-health mailing list